U.S. drugmaker Eli Lilly has signed an agreement worth up to $1.12 billion with Seamless Therapeutics to develop and commercialize treatments for hearing loss using the biotech firm’s gene-editing platform, the Germany-based startup said on Wednesday.
Japanese researchers from Mie University have developed a groundbreaking gene-editing approach that may eliminate the extra chromosome responsible for Down syndrome, according to findings published in PNAS Nexus.
28 Jan 2026-16:18
22 Jul 2025-16:13
